A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia

    June 2024 in “ Advances in therapy
    Hee-Sun Kim, Chae‐Min Ryu, Mase Lee, Kyeong‐Ryoon Lee, Juhee Kim
    Image of study
    TLDR IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
    The study evaluated the safety, pharmacokinetics, pharmacodynamics, and tolerability of IVL3001, a long-acting injectable formulation of finasteride, in 40 healthy adult males with androgenetic alopecia. Participants received a single subcutaneous injection of 12–36 mg IVL3001 and 1 mg finasteride daily for 28 days. Results showed that IVL3001 was well tolerated, maintained consistent plasma concentrations, and effectively reduced dihydrotestosterone levels. The findings suggest that IVL3001 offers advantages over conventional oral finasteride, including rapid onset, sustained drug concentration, and improved compliance.
    Discuss this study in the Community →

    Cited in this study

    17 / 17 results


    5 / 5 results